Navigation Links
K-State research team investigates mutated gene's role in breast cancer
Date:8/9/2010

MANHATTAN, KAN. -- A microscopic gene may play a gigantic role when it comes to cancerous tissue in the human body, according to one Kansas State University research team.

The team is investigating mutation within the ADAM12 gene of the A Disintegrin and Metalloprotease family, or ADAM family, and its role in breast cancer.

"We want to know whether ADAM12 is a good guy or a bad guy in breast cancer," said Anna Zolkiewska, associate professor of biochemistry and research team leader.

If researchers can answer this question about ADAM12, Zolkiewska said it could lead to more effective therapies and treatments due to a better understanding of cancer's components. This, however, hinges on discovering the exact nature of ADAM12, about which little is known. Research has uncovered some interesting information -- and raised more questions, Zolkiewska said.

"Typically human cells have very little ADAM12 protein, but the abundance is suddenly very high in cancer tissue," she said. "When we look even closer, we find a very high level of ADAM12 expression in what we call cancer stem cells. Those cells are the most vicious as they drive the tumor growth."

Although chemotherapy and radiotherapy kill tumors, they are ineffective on the cancer stem cells, Zolkiewska said. Without being surgically removed from the body, the stem cells will grow another tumor over the course of a few years. This again raises the question as to the role of ADAM12.

"Is it helping that tumor re-grow or is it trying to prevent it?" Zolkiewska asks.

Perhaps the most perplexing question the team hopes to solve is why the ADAM12 gene mutates inside cancer tissue.

"Mutation means that one letter in the DNA within the cell has changed," Zolkiewska said. "This is very striking because there are only a handful of human genes that are changed that way in tumors. ADAM12 is one of those genes and the only one among that family."

Zolkiewska said this raises the questions of whether the gene's mutation in cancer tissue is purely a coincidence or is part of a larger role. Prior research by the team indicates ADAM12 is a "good guy" since mutation to the gene effectively kills ADAM12 protein.

"A tumor wants to grow, and from the point of view of the tumor, you want to invade and kill the patient. So you will first take care of those good guys, or those policemen inside the body who protect the patient," Zolkiewska said. "If ADAM12 is one of those good guys, the growing tumor wants to take it out of the picture."

This discovery of mutation rendering ADAM12 dead was a scientific first by the K-State team.

Zolkiewska recently was awarded a three-year grant of $444,000 from the National Institutes of Health to further the research. The grant's title is "Structure-Function Analysis of Breast Cancer-Associated Mutations in ADAM12."

Assisting Zolkiewska in the research are Sara Duhachek Muggy, Manhattan, a graduate student in biochemistry, and Hui Li, who is conducting postdoctoral work. Zolkiewska credited a large portion of the team's findings to Emilia Solomon, Los Alamos, N.M., a December 2009 biochemistry doctoral graduate.


'/>"/>

Contact: Anna Zolkiewska
zolkiea@k-state.edu
785-532-3082
Kansas State University
Source:Eurekalert

Related biology news :

1. K-State research: Freshwater pollution costs US at least $4.3 billion a year
2. Researchers to use K-States BSL-3 Lab for $1 million study of fungus threatening wheat crops
3. K-State biologist collaborating with researchers in Africa on grassland sustainability, biodiversity
4. K-State researchers help Epitopix license the United States first E. coli O157 vaccine for cattle
5. K-State researchers work with university in Ghana to create biofuels from native tree seeds
6. K-State using Second Life island to help high school students learn earth science
7. K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses
8. K-State host to workshop on rapid methods to detect microorganisms in food
9. Researchers from around the globe coming to K-State June 21 for workshop on Fusarium fungus
10. K-State plant pathologists develop online teaching modules used globally
11. K-State researcher, collaborators study virulence of pandemic H1N1 virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... Feb. 2, 2016 Technology Enhancements Accelerate Growth of ... of the digital and computed radiography markets in ... and Indonesia (TIM). It provides ... size, as well as regional market drivers and restraints. ... market penetration and market attractiveness, both for digital and ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... 09, 2016 , ... Creation Technologies, leading global provider of ... Customer Rating Award from Circuits Assembly , today announced its milestone achievement of ... Mexico and China. , The EMS provider, known in the EMS industry for ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: ... Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, ... College (TCMC) will hold an open house for participants to learn about a ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced ... the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to ... heard throughout the drug regulatory review process. , “Adding Diane Dorman is just ...
Breaking Biology Technology: